Tesaro, which is developing drugs for chemotherapy-induced nausea and solid tumors, raised $81 million by offering 6 million shares at $13.50, the midpoint of the range of $12.00 to $15.00. Tesaro plans to list on the NASDAQ under the symbol TSRO. Citi, Morgan...read more
Tesaro, a biotech focused on the treatment of chemotherapy-induced symptoms, announced terms for its IPO on Tuesday. The Waltham, MA-based company plans to raise $81 million by offering 6.0 million shares at a price range of $12 to $15. At the midpoint of the...read more
Tesaro, a biotech focused on the treatment of chemotherapy-induced symptoms, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Waltham, MA-based company, which was founded in 2010, plans to list on the NASDAQ under the...read more
Tesaro prices IPO at $13.50, within the range
Tesaro, which is developing drugs for chemotherapy-induced nausea and solid tumors, raised $81 million by offering 6 million shares at $13.50, the midpoint of the range of $12.00 to $15.00. Tesaro plans to list on the NASDAQ under the symbol TSRO. Citi, Morgan...read more
5 US IPOs planned for the week of Jun 25
The following IPOs are expected to price this week:
EQT Midstream Partners (EQM), which operates natural gas transportation and storage systems in the Appalachian...read more
Biotech Tesaro sets terms for $81 million US IPO
Tesaro, a biotech focused on the treatment of chemotherapy-induced symptoms, announced terms for its IPO on Tuesday. The Waltham, MA-based company plans to raise $81 million by offering 6.0 million shares at a price range of $12 to $15. At the midpoint of the...read more
Biotech Tesaro files for $86 million US IPO
Tesaro, a biotech focused on the treatment of chemotherapy-induced symptoms, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Waltham, MA-based company, which was founded in 2010, plans to list on the NASDAQ under the...read more